ArticleDiscover oncology2026
A GIMAP family signature for prognostic prediction and immune characterization in hepatocellular carcinoma patients.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundGTPase, IMAP family genes (GIMAPFGs) are extensively used for diagnosis and treatment in cancer, their prognostic significance and therapeutic potential in hepatocellular carcinoma (HCC) remain insufficiently explored.
methodsGIMAPFGs associated with HCC prognosis were identified using Cox regression analysis. a prognostic model was constructed through multivariate Cox regression, the model was validated on an independent dataset. followed by an analysis of its biological function. We analyzed variations in tumor immune cell infiltration according to the prognostic signature. Meanwhile, single-cell analysis demonstrated the expression of GIMAPFGs in HCC.
resultsA prognostic risk model was developed using 2 GIMAPFGs (GIMAP1 and GIMAP8) and its prognostic significance was confirmed with an independent external HCC dataset, establishing it as an independent risk factor for HCC patients. This characteristic is also associated with the immune microenvironment of HCC.
conclusionsThis novel GIMAPFGs signature provides a valuable tool for patient stratification and offer a new therapeutic approach for HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.